Trends in solubility of polymorphs

Journal of Pharmaceutical Sciences

Volumn 94, Issue 5, 2005, Pages 929-939

  Pudipeddi, Madhu ^a   Serajuddin, Abu T M ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Polymorphs; Solubility

Indexed keywords

1 METHYL 2 NITRO 5 VINYLIMIDAZOLE; 2 METHYLSORBINIL; 2 [(2 METHYL 1 IMIDAZOLYL)METHYL]BENZO[F]THIOCHROMEN 1 ONE; 2 [4 [2 (5 TETRAZOLYLMETHYL)BENZYLOXY]PHENOXYMETHYL]QUINOLINE; 2,3 DIBROMOPROPIONIC ACID; 2,7 DIHYDRONAPHTHALENE; 3 AMINO 6 METHYL 1 (3 TRIFLUOROMETHYLPHENYL) 1H PYRIDAZIN 4 ONE; 3 NITRO 4 ACETOTOLUIDINE; ACEMETACIN; ACETAMIDE; ACETAZOLAMIDE; AMILORIDE; ANDROSTANEDIONE; ANTHRANILIC ACID; AURANOFIN; AWD 12214; BISACODYL; BROMINE DERIVATIVE; BUTYROPHENONE; CARBOVIR; CHLORAMPHENICOL PALMITATE; CHLOROACETIC ACID; CHLORPROPAMIDE; CINNAMIC ACID; CYCLOPENTHIAZIDE; DIFLUNISAL; DUP 747; E 2101; ETHYL BISCOUMACETATE; ETOPOSIDE; F 2693; FLUCONAZOLE; FLUFENAMIC ACID; FLUPREDNISOLONE; FOSINOPRIL; FUROSEMIDE; GEPIRONE; GLIBENCLAMIDE; GLYBUZOLE; GLYCOLIC ACID; HEXADECANOL; IMIDAZOLE DERIVATIVE; INDOMETACIN; IOPANOIC ACID; LAMIVUDINE; LIFIBROL; LOSARTAN; MEBENDAZOLE; MEFENAMIC ACID; MENADIONE; MEPROBAMATE; METHYLPREDNISOLONE; MORACIZINE; MYRISTYL ALCOHOL; N [[4' [(2 ETHYL 5,7 DIMETHYL 3H IMIDAZO[4,5 B]PYRIDIN 3 YL)METHYL] 2 BIPHENYLYL]SULFONYL]BENZAMIDE; NAPHTHALENE DERIVATIVE; NICLOSAMIDE; NITRO DERIVATIVE; OXYCLOZANIDE; PARA CRESOL; PARACETAMOL; PHENYLBUTAZONE; PIRETANIDE; PIROXICAM; PLECONARIL; PRASTERONE; PREMAFLOXACIN; PROGESTERONE; PROPIONIC ACID DERIVATIVE; PROPRANOLOL; RANITIDINE; RESORCINOL; RITONAVIR; ROXIFIBAN; SALMETEROL; SUCCINYLSULFATHIAZOLE; SULFAMETOXYDIAZINE; SULFATHIAZOLE; SULFUR; TACHYKININ RECEPTOR ANTAGONIST; TAMOXIFEN CITRATE; TENOXICAM; THEOPHYLLINE; TOLBUTAMIDE; TOLUIDINE DERIVATIVE; TRANILAST; UNCLASSIFIED DRUG; URAPIDIL; VERLUKAST; VINYL DERIVATIVE;

CALCULATION; DRUG SOLUBILITY; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; REVIEW; THEORETICAL MODEL;

EID: 20344391910     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20302     Document Type: Note

References (72)

1. Brittain HG, editor. 1999. Polymorphism in pharmaceutical solids. New York: Marcel Dekker.
2. Byrn S, Pfeiffer R, Ganey M, Hoiberg C, Poole JW, Poochikian G. 1995. Pharmaceutical solids: Strategic approach to regulatory considerations. Pharm Res 12:945-954.
3. Yu LX, Furness MS, Raw A, Woodland Outlaw KP, Nashed NE, Ramos E, Miller SPF, Adams RC, Fang F, Patel RM, Holcombe FO Jr, Chiu Y, Hussain AS. 2003. Scientific considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications. Pharm Res 20:531-536.
4. Yu L. 1995. Inferring thermodynamic stability relationship of polymorphs from melting data. J Pharm Sci 84:966-974.
5. Gu CH, Grant DJ. 2001. Estimating the relative stability of polymorphs and hydrates from heats of solution and solubility data. J Pharm Sci 90: 1277-1287.
6. Aguiar AJ, Krc J, Kinkel AW, Samyn JC. 1967. Effect of polymorphism on the absorption of chloramphenicol from chlroamphenicol palmtate. J Pharm Sci 56:847-853.
7. Khalafallah N, Khalil SA, Moustafa MA. 1974. Bioavailability determination of two crystal forms of sulfameter in humans from urinary excretion data. J Pharm Sci 63:861-864.
8. Ali AA, Farouk A. 1981. Comparative studies on dissolution and the bioavailability of ampicillin anhydrate and trihydrate. Int J Pharm 9:239-243.
9. Aguiar AJ, Zelmer JE. 1969. Dissolution behavior of polymorphs of chloramphenicol palmitate and mefenamic acid. J Pharm Sci 58:983-987.
10. Burnette RR, Connors KA. 2000 Statistical properties of thermodynamic quantities for cyclodextrin complex formation. J Pharm Sci 89:1389-1394.
11. Schinzer WC, Bergren MS, Aldrich DS, Chao RS, Dunn MJ, Jeganathan A, Madden LM. 1997. Characterization and interconversion of polymorphs of premafloxacin, a new quinolone antibiotic. J Pharm Sci 86:1426-1431.
12. Panagopoulou-Kalpani A, Malamatris S. 2000. Preparation and characterization of a new polymorphic form and a solvate form of glibenclamide. Int J Pharm 195:239-245.
13. Shefter E, Higuchi T. 1963. Dissolution behavior of crystalline solvated and nonsolvated forms of some pharmaceuticals. J Pharm Sci 52:781-791.
14. Reutzel-Edens SM, Kleemann RL, Lewellen PL, Borghese AL, Antoine LJ. 2003 Crystal forms of LY334370 HCl: Isolation, solid-state characterization, and physicochemical properties. J Pharm Sci 92:1196-1205.
15. Yalkowsky SH. 1999. Solubility and solubilization in aqueous media. New York: Oxford University Press. p 63.
16. Hoffman JD. 1958. Thermodynamic driving force in nucleation and growth processes. J Chem Phys 29: 1192-1193.
17. Hancock BC, Parks M. 2000. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 17:397-403.
18. Amdion GL, Lennernas H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutical drug classification: The correlation of in-vitro drug product dissolution and in-vivo bioavailability. Pharm Res 12:413-420.
19. Brittain HG, Grant DJW. 1999. Effects of polymorphism and solid-state solvation on solubility and dissolution rate. In: Brittain HG. editor. Polymorphism in pharmaceutical solids. New York: Marcel Dekker. pp 279-330.
20. Burger A, Lettenbichler A. 1993. Polymorphism and pseudopolymorphism of acemetacin. Pharmazie 48:262-272.
21. Griesser UJ, Burger A, Mereiter K. 1997. Polymorphic drug substances of the European Pharmacopeia, Part 9: Physicochemical properties and crystal structure of acetazolamide crystal forms. J Pharm Sci 86:352-358.
22. Jozwiakowski MJ, Williams SO, Hathaway RD. 1995. Relative physical stability of the solid forms of amiloride hydrochloride. Int J Pharm 91:195-207.
23. Hagen V, Reck G, Dathe M, Jansch HJ, Feist M. 1992. Potential cardiotonic agents, Part 15: Crystal modifications of 3-cyano-2-morpholino-5-(4-pyridinyl) pyridine (AWD-122-14). Pharmazie 47:777-780.
24. Nguyen NA, Ghosh S, Gatlin LA, Grant DJ. 1994. Physicochemical characterization of the various solid forms of carbovir, an antiviral nucleoside. J Pharm Sci 83:1116-1123.
25. Martinez-Oharriz MC, Martin C, Goni MM, Rodriguez-Espinosa C, Sanchez M. 1994. Polymorphsim of diflunisal: Isolation and solid-state characterization of a new crystal form. J Pharm Sci 83:174-177.
26. Raghavan K, Dwivedi A, Campbell GC, Nemeth G, Hussain MA. 1994. Spectroscopic investigation of DuP-747 polymorphs. J Pharm Biol Med Anal 12:777-785.
27. Kushida I, Ashizawa K. 2002. Solid state characterization of E2101, a novel antispastic drug. J Pharm Sci 91:2193-2202.
28. Shah JC, Chen JR, Chow D. 1999. Metastable polymorphs of Etoposide with higher dissolution rate. Drug Dev Ind Pharm 25:63-67.
29. Chauvet A, Masse J, Ribet JP, Bigg D, Austin JM, Patoiseau JF, Jaud J. 1992. Characterization of polymorphs and solvates of 3-amino-1-(m- trifluoromethylphenyl)-6-methyl-1H-pyridazin-4-one. J Pharm Sci. 81:836-841.
30. Alkhamis KA, Obaidat AA, Nuseirat AF. 2002. Solid-state characterization of fluconazole. Pharm Tech 7:491-503.
31. Bartolomei M. 2000. Solid-state studies on hemihydrate and the anhydrous forms of flunisolide. J Pharm Biomed Anal 24:81-93.
32. Haleblian JK, Koda RT, Biles JA. 1971. Isolation and characterization of solid phases of flurprednisilone. J Pharm Sci 60:1485-1488.
33. Matsuda Y, Tatsumi E. 1990. Physicochemical characterization of furosemide modifications. Int J Pharm 60:11-26.
34. Behme RJ, Brooke D, Farney RF, Kensler TT. 1985. Characterization of polymorphism of gepirone hydrochloride. J Pharm Sci 74:1041-1046.
35. Ito S, Nishimura M, Kobayashi Y, Itai S, Yamamoto K. 1997. Characterization of polymorphs and hydrates of GK-128, a serotonin3 receptor antagonist. Int J Pharm 151:133-143.
36. Suleiman MS, Najib NM. 1989. Isolation and physicochemical characterization of solid forms of glibenclamide. Int J Pharm 50:103-109.
37. Otsuka M, Ofusa T, Matsuda Y. 1999. Physicochemical characterization of glybuzole polymorphs and their pharmaceutical properties. Drug Dev Ind Pharm 25:197-203.
38. Burger A, Lettenbichler A. 2000. Polymorphism and preformulation studies in lifibrol. Eur J Pharm Biopharm 49:65-72.
39. Raghavan K, Dwivedi A, Campbell GC, Johnston E, Levorse D, McCauley JA, Hussain M. 1993. Spectroscopic Investigation of losartan polymorphs. Pharm Res 10:900-904.
40. Swanepoel E, Liebenberg W, Dewarakonda B, De Villiers MM. 2003. Developing a discriminating dissolution test for three mebendazole polymorphs based on solubility differences. Pharmazie 58: 117-121.
41. Higuchi WI, Lau PK, Higuchi T, Shell JW. 1963. Polymorphism and drug availability: Solubility relations in the methylprednisolone system. J Pharm Sci 52:150-153.
42. Ghodbane S, McCauley JA. 1990. Study of the polymorphism of 3-((3-(2-(7-chloro-2-quinolinyl)-(E)-ethenyl)phenyl)((3-dimethylamino-3 oxopropyl) thio)methyl)-thio)propanoic yl)thio)methyl)-thio)-propanoic acid (MK571) by DSC, TG, XRPD and solubility measurements. Int J Pharm 59:281-286.
43. Jahansouz H, Thompson KC, Brenner GS, Kauffman MJ. 1999. Investigation of the polymorphism of the angiotensin II antagonist agent MK-996. Pharm Dev Tech 4:181-187.
44. Wu LS, Torosian G, Sigvardson K, Gerard C, Hussain MA. 1994. Investigation of moricizine hydrochloride polymorphs. J Pharm Sci 83:1404-1406.
45. van Tonder EC, Maleka TSP, Liebenberg W, Song M, Wurster DE, De Villiers MM. 2004. Preparation and physicochemical properties of niclosamide anhydrate and two monohydrates. Int J Pharm 269:417-432.
46. Wang Y, Wenslow RM, McCauley JA, Crocker LS. 2002. Polymorphic behavior of an NK1 receptor antagonist. Int J Pharm 243:147-159.
47. Chikaraishi Y, Otsuka M, Matsuda Y. 1995. Dissolution behavior of piretanide polymorphs at various temperatures and pHs. Chem Pharm Bull 43:1966-1969.
48. Vrecer F, Vrbinc M, Meden A. 2003. Characterization of piroxicam crystal modifications. Int J Pharm 256:3-15.
49. Bartolomei M, Bertocchi P, Ramusino MC, Santucci N, Valvo L. 1999. Physicochemical characterization of the modification I and II of (R,S) propranolol hydrochloride: solubility and dissolution studies. J Pharm Biomed Anal 21:299-309.
50. Madan T, Kakkar AP. 1994. Preparation and characterization of ranitidine hydrochloride crystals. Drug Dev Ind Pharm 20:1571-1588.
51. Carlton RA, Difeo TJ, Powner TH, Santos I, Thompson MD. 1996. Preparation and characterization of polymorphs for an LTD4 antagonist, RG 12525. J Pharm Sci 85:461-467.
52. Bauer J, Spanton S, Henry R, Quick J, Morris J. 2001. Ritonavir: An extrordinary example of conformational polymoprhism. Pharm Res 18:859-866.
53. Maurin MB, Vickery RD, Rabel SR, Rowe SM, Foris CM. 2002. Polymorphism of roxifiban. J Pharm Sci 91:2599-2604.
54. Tong HH, Shekunov BY, York P, Chow AH. 2001. Characterization of two polymorphs of salmeterol xinofoate crystallized from supercritical fluids. Pharm Res 18:852-858.
55. Byrn S, Pfeifer RR, Stowell JG. 1999. Polymorphs. In: Byrn S, Pfeiffer RR, Stowell RR, editors. Solid-state chemistry of drugs. West Lafayette, IN: SSCI, Inc., pp 143-232.
56. Lagas M, Lerk CF. 1981. The polymorphism of sulfathiazole. Int J Pharm 8:11-24.
57. Milosovich G. 1964. Determination of solubility of a metastable polymorph. J Pharm Sci 53:11-24.
58. Cantera RG, Leza MG, Bachiller CM. 2002. Solid phases of tenoxicam. J Pharm Sci 91:2240-2251.
59. Kimura K, Hirayama F, Uekama K. 1999. Characterization of tolbutamide polymorphs (Burger's Forms II and IV) and polymorphic transition behavior. J Pharm Sci 88:385-391.
60. Rowe EL, Anderson BD. 1984. Thermodynamic studies of tolbutamide polymorphe. J Pharm Sci 73: 1673-1675.
61. Rollinger JM, Gstrein EM, Burger A. 2002. Crystal forms of toresamide: New insights. Eur J Pharm Biopharm 53:75-86.
62. Kawashima Y, Niwa T, Takeuchi H, Hino T, Itoh Y, Furuyama S. 1991. Characterization of polymorphs of tranilast anhydrate and tranilast monhydrate when crystallized by two solvent change spherical crystallization techniques. J Pharm Sci 80:472-478.
63. Rocco WL, Swanson JR. 1995. WIN63843 polymorphs: prediction of enantiotropy. Int J Pharm 117:231-236.
64. Zhu H, Grant DJW. 1996. Influence of water activity in organic solvent + water mixture on the nature of the crystalline drug phase 2. Ampicillin Int J Pharm 139:33-43.
65. Dugue J, Ceolin R, Rouland JC, Lepage F. 1991. Polymorphism of carbamazepine: Solid-state studies on carbamazepine dihydrate. Pharm Acta Helv 66:307-310.
66. Fukumori Y, Fukuda T, Yamamoto Y, Shigitani Y, Hanyu Y, Takeuchi Y, Sato N. 1983. Physical characterization of erythromycin dihydrate, anhydrate and amorphous solid and their dissolution properties. Chem Pharm Bull 31:4029-4039.
67. Di Martino P, Barthelemy C, Palmieri GF, Martelli S. 2001. Physical characterization of naproxen sodium hydrate and anhydrate forms. Eur J Pharm Sci 14:293-300.
68. Caira KC, Robbertse Y, Bergh JJ, Song M, De Villiers MM. 2003. Structural characterization, physicochemical properties, and thermal stability of three crystal forms of nifedipine. J Pharm Sci 92:2519-2533.
69. Fokkens JG, van Amelsfoort JGM, de Blaey CJ, de Kruif CG, Wilting J. 1983. A thermodynamic study of the solubility of theophylline and its hydrate. Int J Pharm 14:79-92.
70. Chang LC, Caira MR, Guillory JK. 1995. Solid-state characterization of dehydroepiandrosterone. J Pharm Sci 84:1169-1179.
71. Brittain HG, Morris KR, Bugay DE, Thakur AB, Serajuddin ATM. 1993. Solid-state NMR and IR for the analysis of pharmaceutical solids: polymorphs of fosinopril sodium. J Pharm Biomed Anal 11: 1063-1069.
72. Giordano F, Gazzaniga A, Moyano JR, Ventura P, Zanol M, Peveri T, Carima L. 1998. Crystal forms of piroxicam pivalate: Preparation and characterization of two polymorphs. J Pharm Sci 87:333-337.